Pelvic exenteration for gynecologic malignancies: The experience of a tertiary center from Greece.


Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 03 11 2021
revised: 15 12 2021
accepted: 28 12 2021
pubmed: 23 1 2022
medline: 17 3 2022
entrez: 22 1 2022
Statut: ppublish

Résumé

Pelvic exenteration is an ultraradical procedure that is performed for locally advanced pelvic malignancies. Despite its rarity, the rates of the procedure increase during the last years due to the gain of surgical expertise. Data on survival rates remain; however, scarce in the literature. We retrospectively reviewed the records of all patients who underwent exenterative procedures for advanced gynecologic malignancies between 2006 and 2020. Major and minor perioperative complications were documented according to the Clavien-Dindo classification only when they occurred during a time limit of 30 days from the operation. Cox regression analysis and Kaplan-Meier survival curves were used for the analysis of survival outcomes. Overall, we identified 138 patients who were offered a pelvic exenteration procedure that were followed up for a median of 42 months (range 6-60 months). Seventy-five patients recurred (54.3%) during the follow-up period within 35.04 months (95% CI 31.01, 39.07 months). After examining several potential factors that might influence survival rates, we observed that only patients with positive margins had increased risk of recurrence (HR 1.66, 95%CI 1.10, 2.56 p = .016), although this was not associated with a decrease in overall survival. Overall survival outcomes were available for 112 patients of whom 62 died (55.4%) within 38.84 months (95% CI 35.02, 42.67). Major complications were detected in 21 patients. Reoperation was required in 18 patients. Anastomotic leakage was observed in 7 cases (5%) of whom 4 patients required reoperation. In summary, the findings of our study suggest that women undergoing pelvic exenteration for gynecologic malignancies have a significant survival probability that is accompanied by acceptable rates of operative morbidity.

Sections du résumé

BACKGROUND BACKGROUND
Pelvic exenteration is an ultraradical procedure that is performed for locally advanced pelvic malignancies. Despite its rarity, the rates of the procedure increase during the last years due to the gain of surgical expertise. Data on survival rates remain; however, scarce in the literature.
METHODS METHODS
We retrospectively reviewed the records of all patients who underwent exenterative procedures for advanced gynecologic malignancies between 2006 and 2020. Major and minor perioperative complications were documented according to the Clavien-Dindo classification only when they occurred during a time limit of 30 days from the operation. Cox regression analysis and Kaplan-Meier survival curves were used for the analysis of survival outcomes.
RESULTS RESULTS
Overall, we identified 138 patients who were offered a pelvic exenteration procedure that were followed up for a median of 42 months (range 6-60 months). Seventy-five patients recurred (54.3%) during the follow-up period within 35.04 months (95% CI 31.01, 39.07 months). After examining several potential factors that might influence survival rates, we observed that only patients with positive margins had increased risk of recurrence (HR 1.66, 95%CI 1.10, 2.56 p = .016), although this was not associated with a decrease in overall survival. Overall survival outcomes were available for 112 patients of whom 62 died (55.4%) within 38.84 months (95% CI 35.02, 42.67). Major complications were detected in 21 patients. Reoperation was required in 18 patients. Anastomotic leakage was observed in 7 cases (5%) of whom 4 patients required reoperation.
CONCLUSION CONCLUSIONS
In summary, the findings of our study suggest that women undergoing pelvic exenteration for gynecologic malignancies have a significant survival probability that is accompanied by acceptable rates of operative morbidity.

Identifiants

pubmed: 35065392
pii: S0960-7404(21)00191-2
doi: 10.1016/j.suronc.2021.101702
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101702

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Dimitrios Haidopoulos (D)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, Athens, Greece.

Vasilios Pergialiotis (V)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, Athens, Greece. Electronic address: pergialiotis@yahoo.com.

Kyveli Aggelou (K)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, Athens, Greece.

Nikolaos Thomakos (N)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, Athens, Greece.

Nikolaos Alexakis (N)

First Department of Propaedeutic Surgery, National Kapodistrian University of Athens, Hippocration Hospital, Athens, Greece.

Emmanouil Stamatakis (E)

Department of Anesthesiology, "Alexandra" General Hospital, Athens, Greece.

Alexandros Rodolakis (A)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH